Anticonvulsant drugs for generalized tonic-clonic epilepsy

References

• Pittau F, Mégevand P, Sheybani L, et al. Mapping epileptic activity: sources or networks for the clinicians? Front Neurol. 2014;5:218.
   PubMed Web of Science ®Google Scholar
• Smith EH, Schevon CA. Toward a mechanistic understanding of epileptic networks. Curr Neurol Neurosci Rep. 2016;16(11):97.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–155.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015;85(11):950–957.
   PubMed Web of Science ®Google Scholar
• Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia. 2005;46(Suppl 9):161–168.
   PubMed Web of Science ®Google Scholar
• Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension. Epilepsy Res. 2016;130:13–20.
   PubMed Web of Science ®Google Scholar
• Christe W 1, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26(3):451–460.
   PubMed Web of Science ®Google Scholar
• Marson AG, Williamson PR, Hutton JL, et al. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev. 2000;(3):CD001030.
   PubMedGoogle Scholar
• Nolan SJ, Marson AG, Weston J, et al. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database Syst Rev. 2016;4:CD001769.
   PubMedGoogle Scholar
• Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav. 2007;10(4):547–552.
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand. 2007;115(3):204–208.
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–1026.
   PubMed Web of Science ®Google Scholar
• Sala-Padró J, Toledo M, Santamarina E, et al. Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy. Clin Neuropharmacol. 2016;39(6):299–301.
   PubMed Web of Science ®Google Scholar
• Giri VP, Giri OP, Khan FA, et al. Acid versus lamotrigine as first-line monotherapy in newly diagnosed idiopathic generalized tonic -clonic seizures in adults - a randomized controlled trial. J Clin Diagn Res. 2016;10(7):FC01–FC04.
   PubMed Web of Science ®Google Scholar
• Brigo F, Igwe SC. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and addolescents. Cochrane Database Syst Rev. 2017;14:2.
   Google Scholar
• Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002;43(9):993–1000.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Ueberall MA, Siemes H, et al. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure. 2005;14(8):597–605.
   PubMed Web of Science ®Google Scholar
• Saetre E, Perucca E, Isojärvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48(7):1292–1302.
   PubMed Web of Science ®Google Scholar
• Rosenow F, Schade-Brittinger C, Burchardi N, et al. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy–an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83(11):1093–1098.
   PubMed Web of Science ®Google Scholar
• Nolan SJ, Tudur Smith C, Weston J, et al. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2016;11:CD001031.
   PubMedGoogle Scholar
• Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9(2):80–87.
   PubMed Web of Science ®Google Scholar
• Verdru P, Wajgt A, Delgado JS, et al. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures. Epilepsia. 2005;46:56.
   Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69:1751–1760.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402–408.
   PubMed Web of Science ®Google Scholar
• Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70(8):607–616.
   PubMed Web of Science ®Google Scholar
• Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia. 2012;53(1):111–119.
   PubMed Web of Science ®Google Scholar
• Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013;84(10):1138–1147.
   PubMed Web of Science ®Google Scholar
• Droz-Perroteau C. The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol. 2011;71:121–127.
   PubMed Web of Science ®Google Scholar
• Droz-Perroteau C, Marchal C, Dureau-Pournin C, et al. Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users. Pharmacoepidemiol Drug Saf. 2012;21:1183–1189.
   PubMed Web of Science ®Google Scholar
• Kang BS, Moon HJ, Kim YS, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disorders. 2013;15:302–310.
   PubMed Web of Science ®Google Scholar
• Sunwoo JS, Park BS, Ahn SJ, et al. Three-year retention rates of levetiracetam, topiramate, and oxcarbazepine: a retrospective hospital-based study. Clin Neuropharmacol. 2017;40:56–62.
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
   PubMed Web of Science ®Google Scholar
• Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia. 2010;51(10):1970–1977.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Topiramate YTC-E Study Group. A doubleblind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin. Epilepsia. 1997;38(suppl 3):60.
   Google Scholar
• Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology. 1999;52(7):1330–1337.
   PubMed Web of Science ®Google Scholar
• Montouris GD, Biton V, Rosenfeld WE. Nonfocal generalized tonic-clonic seizures: response during long-term topiramatetreatment. Topiramate YTC/YTCE Study Group. Epilepsia. 2000;41(Suppl 1):S77–S81.
   PubMed Web of Science ®Google Scholar
• Ohtahara S. Zonisamide in the management of epilepsy–Japanese experience. Epilepsy Res. 2006;68(Suppl 2):S25–S33.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure. 2004;13(Suppl 1):S41-S48; discussion S49.
   PubMed Web of Science ®Google Scholar
• Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004;6(4):267–270.
   PubMed Web of Science ®Google Scholar
• Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res. 1996;25(3):191–197.
   PubMed Web of Science ®Google Scholar
• Eisai US. FDA approves Eisai’s antiepileptic agent Fycompa as adjunctive treatment for primary generalized tonic-clonic seizures. 2015. Press release. NDA 202834/S-005. FDA Approved Labeling Text dated 6/19/2015.
   Google Scholar
• Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav. 2016;61:41–45.
   PubMed Web of Science ®Google Scholar
• Shah E, Reuber M, Goulding P, et al. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure. 2016;34:1–5.
   PubMed Web of Science ®Google Scholar
• Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16:43–54.
   PubMed Web of Science ®Google Scholar
• Brigo F. Lacosamide monotherapy for newly diagnosed epilepsy. Lancet Neurol. 2017;16:20–22.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 2008;54:715–720.
   PubMed Web of Science ®Google Scholar
• Markham A. Brivaracetam: first global approval. Drugs. 2016;76:517–522.
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38–46.
   PubMed Web of Science ®Google Scholar
• Steinig I, Von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicentre cohort study from Germany. Epilepsia. 2017. DOI:10.1111/epi.13768
   PubMedGoogle Scholar
• Viinikainen K, Eriksson K, Mönkkönen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006;9:636–640.
   PubMed Web of Science ®Google Scholar
• Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56:1006–1019.
   PubMed Web of Science ®Google Scholar